GlassScriptPhysician profile
Matthew Scott Brown
NPI 1366944027
$4,315.70
in general payments reported to CMS, 2019-2025
17 companies · $217 in 2025
The $217 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $129 · 2022: $435 · 2023: $2,737 · 2024: $798 · 2025: $217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,626 · Travel and Lodging: $1,081 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,626.11 |
| Travel and Lodging | $1,080.68 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,602.26 | 2022-2025 | Intellis Adaptivestim, Vectris Surescan, Synchromedii |
| Boston Scientific Corporation | $763.66 | 2022-2025 | Wavewriter Alpha Prime 16, Artisan |
| Collegium Pharmaceutical, INC. | $229.98 | 2022-2025 | Belbuca, Nucynta |
| Scilex Pharmaceuticals INC. | $149.43 | 2023-2025 | Ztlido |
| Astrazeneca Pharmaceuticals LP | $100.00 | 2021 | |
| Abbvie INC. | $89.06 | 2023-2025 | |
| Forte Bio-Pharma LLC | $67.37 | 2023-2025 | Prolate, Nalocet, Tanlor |
| Grt US Holding, INC. | $57.51 | 2022 | |
| Si-Bone, INC. | $53.64 | 2023-2024 | |
| Spr Therapeutics, INC | $40.00 | 2022 | |
| Amarin Pharma, INC. | $32.78 | 2023 | |
| Azurity Pharmaceuticals, INC. | $31.47 | 2023-2024 | Horizant, Horizant |
| Vertex Pharmaceuticals Incorporated | $31.32 | 2024-2025 | |
| Valinor Pharma, LLC | $22.36 | 2023 | Movantik |
| Glaxosmithkline, LLC. | $16.25 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Virtus Pharmaceuticals LLC | $15.53 | 2023 | Levorphanol Tartrate |
| Merck Sharp & Dohme LLC | $13.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.